アブストラクト
Japanese
| Title | 新型コロナウイルス感染症 (COVID-19) と小児リウマチ性疾患に関する話題 |
|---|---|
| Subtitle | 解説論文 |
| Authors | 佐藤智*1 |
| Authors (kana) | |
| Organization | *1埼玉県立小児医療センター感染免疫・アレルギー科 |
| Journal | 小児リウマチ |
| Volume | 12 |
| Number | 1 |
| Page | 41-49 |
| Year/Month | 2021 / |
| Article | 報告 |
| Publisher | 日本小児リウマチ学会 |
| Abstract | 「要旨」 新型コロナウイルス感染症(COVID-19)が初めて報告されて2年が経つ. これまでCOVID-19に関して一般小児年齢層での重症化は本邦を含め報告されていない. COVID-19の小児リウマチ性疾患に対する影響も限定的であり, パンデミック下においても安定した診療・治療ができている. 一方でCOVID-19後に小児多系統炎症性症候群(MIS-C/PIMS)という高サイトカイン血症を伴う新たな疾患が報告された. 本稿では現時点でのCOVID-19と小児リウマチ性疾患と診療に関する知見をまとめて解説する. |
| Practice | 臨床医学：内科系 |
| Keywords | COVID-19, MIS-C, リウマチ, 膠原病 |
English
| Title | A review of COVID-19 in children including rheumatic disease. |
|---|---|
| Subtitle | REVIEW PAPER |
| Authors | Satoshi Sato*1 |
| Authors (kana) | |
| Organization | *1Department of Infectious Diseases and Immunology, Saitama Children’s Medical Center |
| Journal | The Journal of Clinical Pediatric Rheumatology |
| Volume | 12 |
| Number | 1 |
| Page | 41-49 |
| Year/Month | 2021 / |
| Article | Report |
| Publisher | Pediatric Rheumatology Association of Japan |
| Abstract | Coronavirus disease 2019 (COVID-19) is the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which appeared in Wuhan, China, in December 2019 and has continued to spread rapidly around the world. Although the majority of COVID-19 in children are mild, there are many important unanswered questions. And the influence of COVID-19 against pediatric rheumatic diseases is also limited. On the other hand, after COVID-19, a new disease with multisystem inflammatory syndrome in children (MIS-C/PIMS) was reported. In this article, this review highlights the current findings on COVID-19, pediatric rheumatic diseases and medical care. |
| Practice | Clinical internal medicine |
| Keywords | COVID-19, MIS-C |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) O'Driscoll M, Santos GRD, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590:140-145.
- 2) 新型コロナウイルス感染症COVID-19診療の手引き第3版. https://www.mhlw.go.jp/content/000668291.pdf
- 3) Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607-1608.
- 4) Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet, 2020;395:1771-1778.
- 5) Belhadjer Z, Meot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV- 2 pandemic. Circulation. 2020;142:429-436.
残りの64件を表示する
- 6) Licciardi F, Pruccoli G, Denina M, et al. SARS-CoV-2-Induced Kawasaki-like hyperinflammatory syndrome: A novel COVID phenotype in children. Pediatrics. 2020;146:e20201711.
- 7) Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. Pediatr Infect Dis J. 2020;39:355-368.
- 8) Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.
- 9) 厚生労働省ホームページより,新型コロナウイルス感染症の国内発生動向(速報値) https://www.mhlw.go.jp/content/10906000/000851723.pdf
- 10) Katsuta T, Shimizu N, Okada K, et al. The clinical characteristics of pediatric coronavirus disease 2019 in 2020 in Japan. Pediatr Int. 2021;7:10.1111/ped.14912. doi: 10.1111/ped.14912
- 11) Imamura T, Saito M, Ko YK, et al. Roles of Children and Adolescents in COVID-19 Transmission in the Community: A Retrospective Analysis of Nationwide Data in Japan. Front Pediatr. 2021;9:705882.
- 12) Zhen-Dong Y, Gao-Jun Z, Run-Ming J, et al. Clinical and transmission dynamics characteristics of 406 children with coronavirus disease 2019 in China: A review. J Infect. 2020;81:e11-e15.
- 13) Kabeerdoss J, Pilania RK, Karkhele R, et al. Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: Immunological mechanisms, clinical manifestations and management. Rheumatol Int. 2021;41:19-32.
- 14) Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020. doi: 10.1001/jamaoncol.2020.2028
- 15) Hrusak O, Kalina T, Wolf J, et al. Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. Eur J Cancer. 2020;132:11-16.
- 16) Minotti C, Tirelli F, Barbieri E, et al. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect. 2020. doi: 10.1016/j.jinf.2020.04.026
- 17) D'Antiga L. Coronaviruses and immunosuppressed patients: The facts during the third epidemic. Liver Transpl. 2020. doi: 10.1002/It.25756
- 18) Tannuri U, Tannuri ACA, Cordon MNA, et al. Low incidence of COVID-19 in children and adolescent post-liver transplant at a Latin American reference center. Clinics (Sao Paulo). 2020;75:e1986.
- 19) Harter G, Spinner CD, Roider J, et al. COVID-19 in people living with human immunodeficiency virus: A case series of 33 patients. Infection. 2020. doi: org/10.1007/s15010-020-01438-z.
- 20) Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: A national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021;9:699-711.
- 21) Leora R. Feldstein, Mark W, et al. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325:1-14.
- 22) Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet, 2020;395:1607-1608.
- 23) Dolinger MT, Person H, Smith R, et al. Pediatric Crohn's disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. J Pediatr Gastroenterol Nutr. 2020;71:153-155.
- 24) Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV- 2 epidemic: An observational cohort study. The Lancet, 2020;395:1771-1778.
- 25) Chiotos K, Bassiri H, Behrens EM, et. al. Multisystem Inflammatory syndrome in children during the coronavirus 2019 pandemic: A case series. J Pediatric Infect Dis Soc. 2020;9:393-398.
- 26) Gruber CN, Patel RS, Trachtman R, et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell. 2020;183:982-995.e14.
- 27) Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183:968-981.e7.
- 28) Diorio C, Henrickson SE, Vella LA, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. 2020;130:5967-5975.
- 29) Hoste L, Van Paemel R, Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: A systematic review. Eur J Pediatr. 2021;180:2019-2034.
- 30) Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev. 2021;38:51-57.
- 31) Henderson LA, Yeung RSM. MIS-C: early lessons from immune profiling. Nat Rev Rheumatol. 2021;17:75-76.
- 32) 川崎病学会運営委員を対象とした川崎病とSARS-CoV-2との関連についてのアンケート調査の結果について.日本川崎病学会. http://www.jskd.jp/pdf/KD-COVID-Questionnaire0108.pdf
- 33) Takasago S, Sakai A, Sugiyama M, et al. Case Report: Changes in Cytokine Kinetics During the Course of Disease in a Japanese Patient With Multisystem Inflammatory Syndrome in Children. Front Pediatr. 2021;9:702318. doi: 10.3389/fped.2021.702318. eCollection 2021.
- 34) Uchida M, Kashima Y, Mochizuki K, et al. Multisystem Inflammatory Syndrome in Children - A New Syndrome Complicated With Acute Heart Failure Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2) Infection. Circ J. 2021;85:948-952.
- 35) Fukuda S, Kaneta M, Miyake M, et al. A case of multisystem inflammatory syndrome in children in a Japanese boy: With discussion of cytokine profile. Mod Rheumatol Case Rep. 2021; 5:442-447.
- 36) Baba T, Maruyama T, Katsuragi S, et al. Multisystem inflammatory syndrome associated with SARS-CoV-2 in a Japanese girl. Pediatr Int. 2021;10.1111/ped.14704. doi: 10.1111/ped.14704. Online ahead of print.
- 37) Wald ER, Schmit KM, Gusland DY. A Pediatric Infectious Disease Perspective on COVID-19. Clin Infect Dis. 2021;72:1660-1666.
- 38) Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. Royal College of Paediatrics and Child Health. https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf
- 39) Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). Health Alert Network(HAN). https://emergency.cdc.gov/han/2020/han00432.asp
- 40) Multisystem inflammatory syndrome in children and adolescents with COVID-19 Scientific Brief. World Health Organization. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
- 41) 小児COVID-19関連多系統炎症性症候群(MIS-C/PIMS)診療コンセンサスステートメント.日本小児科学会. http://www.jpeds.or.jp/modules/activity/index.php?content_id=391
- 42) Radia T, Williams N, Agrawal P, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev. 2021;38:51-57.
- 43) Schlapbach LJ, Andre MC, Grazioli S, et al. Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C)in Switzerland. Front. Pediatr. 2021. https://doi.org/10.3389/fped.2021.667507
- 44) McArdle AJ, Vito O, Patel H, et al. Treatment of Multisystem Inflammatory Syndrome in Children. N Engl J Med. 2021;385:11-22.
- 45) Son MBF, Murray N, Friedman K, et al. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med. 2021;385:23-34.
- 46) Ouldali N, Toubiana J, Antona D, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 2021;325:855-864.
- 47) Nozawa T, Imagawa T, Ito S. Coronary-Artery Aneurysm in Tocilizumab-Treated Children with Kawasaki's Disease. N Engl J Med. 2017;377:1894-1896.
- 48) Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis Rheumatol. 2020;72:1791-1805.
- 49) Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol. 2021;73:e13-e29.
- 50) Developed by the ACR MIS-C and COVID-19 Related Hyperinflammation Task Force. Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV- 2 and Hyperinflammation in COVID-19: Version 3. https://www.rheumatology.org/Portals/0/Files/ACR-COVID-19-Clinical-Guidance-Summary-MIS-C-Hyperinflammation.pdf.
- 51) Hyrich KL, Machado PM. Rheumatic disease and COVID-19: Epidemiology and outcomes. Nat Rev Rheumatol. 2021;17:71-72.
- 52) Yazdany J. COVID-19 in Rheumatic Diseases: A Research Agenda. Arthritis Rheumatol. 2020;72:1596-1599.
- 53) Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859-866.
- 54) Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150-154.
- 55) Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
- 56) Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:732-739.
- 57) Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.
- 58) Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University (Medical Sciences). 2020;49. doi: 10.3785/j.issn.1008-9292.2020.03.03.
- 59) Yazdany J, Alfred H J Kim. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020;172:754-755.
- 60) Sozeri B, Ulu K, Kaya-Akca U, et al. The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: A retrospective and multicenter study. Rheumatol Int. 2021;27:1-7.
- 61) Calvo C, Udaondo C. COVID-19 in Children With Rheumatic Diseases in the Spanish National Cohort EPICO-AEP. J Rheumatol. 2021;48:1190-1192.
- 62) Villacis-Nunez DS, Rostad CA, Rouster-Stevens K, et al. Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases. Pediatr Rheumatol Online J. 2021;19:94. doi: 10.1186/s12969-021-00568-4.
- 63) Curtis JR, Johnson SR, Anthony DD, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. Arthritis Rheumatol. 2021.
- 64) European Alliance of Associations for Rheumatology (EULAR). View-points on SARS-CoV2 vaccination in patients with RMDs. 5. Paediatric Rheumatology
- 65) European Association (PRES). Guidelines and Recommendations. PRES update regarding COVID-19 vaccines in 3 pediatric rheumatic patients. Published on 30 December 2020.
- 66) Furer V, Rondaan C, Agmon-Levin N, et al. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open. 2021;7:e001594.
- 67) Dimopoulou D, Spyridis N, Vartzelis G, et al. Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. 2021. doi: 10.1002/art.41977. Online ahead of print.
- 68) Wahezi DM, Lo MS, Rubinstein TB, et al. American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol. 2020;72:1809-1819.
- 69) Wahezi DM, Lo MS, Rubinstein TB, et al. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol. 2021;73:e46-e59.
